Holen Sie sich die Stockscreener-App
1.71
7.07%
-0.13
Schlusskurs vom Vortag:
$1.84
Offen:
$1.89
24-Stunden-Volumen:
9.10M
Relative Volume:
1.16
Marktkapitalisierung:
$516.26M
Einnahmen:
$188.87M
Nettoeinkommen (Verlust:
$-400.38M
KGV:
-1.14
EPS:
-1.5
Netto-Cashflow:
$-260.90M
1W Leistung:
-6.04%
1M Leistung:
-19.72%
6M Leistung:
+33.59%
1J Leistung:
+15.54%
1-Tages-Spanne:
$1.65
$2.00
1-Wochen-Bereich:
$1.65
$2.00
52-Wochen-Spanne:
$0.8511
$2.73
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Firmenname
Pacific Biosciences Of California Inc
Sektor
Branche
Telefon
650-521-8000
Adresse
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.71 | 555.51M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
112.68 | 193.83B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
366.05 | 140.01B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
99.49 | 129.33B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.73 | 109.92B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
75.87 | 44.36B | 6.07B | 1.06B | 799.60M | 1.8527 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-11 | Herabstufung | UBS | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-22 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-04-18 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-14 | Eingeleitet | Guggenheim | Neutral |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-11-17 | Hochstufung | UBS | Neutral → Buy |
| 2023-10-31 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-09-28 | Eingeleitet | Bernstein | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-06-30 | Eingeleitet | Goldman | Buy |
| 2023-05-10 | Eingeleitet | Barclays | Equal Weight |
| 2023-03-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2023-01-20 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-01-21 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-09-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-11-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-10-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-02 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-03-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-10-15 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-04-02 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2018-10-19 | Eingeleitet | Cowen | Outperform |
| 2017-11-03 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-28 | Herabstufung | CL King | Buy → Neutral |
| 2016-11-03 | Bestätigt | Cantor Fitzgerald | Buy |
| 2016-06-27 | Eingeleitet | CL King | Buy |
| 2016-04-15 | Eingeleitet | First Analysis Sec | Overweight |
| 2016-02-04 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2016-01-04 | Bestätigt | Cantor Fitzgerald | Buy |
| 2015-10-23 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2015-08-27 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-02-04 | Bestätigt | Maxim Group | Buy |
| 2013-09-26 | Bestätigt | Maxim Group | Buy |
| 2013-01-14 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Pacific Biosciences Of California Inc Aktie (PACB) Neueste Nachrichten
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2025 Earnings Call Transcript - Insider Monkey
Slammed 28% Pacific Biosciences of California, Inc. (NASDAQ:PACB) Screens Well Here But There Might Be A Catch - 富途牛牛
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 6.8%What's Next? - MarketBeat
Pacific Biosciences of California: Navigating Market Waves Amid Revenue Hurdles - StocksToTrade
PACB Q4 Deep Dive: Consumables and Clinical Adoption Drive Growth as SparkNex Launch Nears - Finviz
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up - TradingView
Pacific Biosciences of California, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
PacBio Q4 2025 slides: Revenue growth and margin expansion driven by human genomics - Investing.com Canada
Pacific Biosciences's Q4 And Full-Year Revenue Improves - Nasdaq
PacBio Announces Fourth Quarter and Full Year 2025 Financial Results - The Globe and Mail
Pacific Biosciences of California Inc (PACB) Q4 2025 Earnings Ca - GuruFocus
PacBio (PACB) Q4 2025 Earnings Call Transcript - The Globe and Mail
PacBio (NASDAQ:PACB) Reports Strong Q4 CY2025 - The Globe and Mail
Pacific Biosciences of California Q4 2025 Earnings Call Transcript - MarketBeat
Pacific Biosciences of California Q4 Earnings Call Highlights - MarketBeat
Pacific Biosciences of California (PACB) reports Q4 loss, beats revenue estimates - MSN
Earnings call transcript: Pacific Biosciences beats Q4 2025 forecasts By Investing.com - Investing.com Canada
PACB: Record consumable growth and SparkNex launch set stage for 8% revenue growth in 2026 - TradingView
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Pacific Biosciences of California (NASDAQ:PACB) Announces Earnings Results - MarketBeat
Pacific Biosciences: Q4 Earnings Snapshot - kens5.com
PacBio (PACB) Surpasses Q4 Revenue Expectations Amid Strategic E - GuruFocus
PacBio (NASDAQ: PACB) lifts 2025 revenue but posts large restructuring-driven loss - Stock Titan
Pacific Biosciences of California joins iHope to expand genomic sequencing access - Traders Union
PacBio tech joins iHope to help rare disease patients get answers - Stock Titan
Valuation Update: Is Freedom Holding Corp in a bullish channelEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
What analyst consensus says on Pacific Biosciences of California Inc. stockRate Hike & Accurate Technical Buy Alerts - mfd.ru
Pacific Biosciences: Fourth Quarter Earnings Overview - Bitget
How strong is Pacific Biosciences of California Inc. stock revenue growth2025 Stock Rankings & Risk Controlled Stock Alerts - mfd.ru
PacBio Earnings: What To Look For From PACB - Finviz
Pacific Biosciences of California (NASDAQ:PACB) Is Carrying A Fair Bit Of Debt - 富途牛牛
How The Narrative Around Pacific Biosciences Of California (PACB) Is Shifting As Assumptions Evolve - Yahoo Finance
Buyback Watch: Will BIIB benefit from sector rotationPortfolio Value Summary & Daily Growth Stock Investment Tips - baoquankhu1.vn
Pacific Biosciences of California (PACB) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Risk Recap: Can Pacific Biosciences of California Inc. reach all time highs this yearWeekly Earnings Recap & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Pacific Biosciences showcases automation options at SLAS2026 - Traders Union
Pacific Biosciences Announces Interim Leadership Role Realignment - TipRanks
PacBio sells short-read DNA sequencing assets to Illumina for $48.1m - Investing.com Nigeria
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 7.7%Here's Why - MarketBeat
Pacific Biosciences Sees Strategic Maneuvers Amid Financial Woes - StocksToTrade
Pacific Biosciences of California Closes $48.1 Million Sale of DNA Sequencing Assets to Illumina - marketscreener.com
PacBio (PACB) Finalizes Asset Sale to Illumina, Secures $48.1 Mi - GuruFocus
Pacific Biosciences Strengthens Balance Sheet via Asset Sale - TipRanks
Pacific Biosciences of California Signs Asset Purchase Agreement With Illumina Cambridge - TradingView
PacBio Completes Sale of Short-Read Sequencing Assets to Illumina for $48.1 Million - Quiver Quantitative
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Pacific Biosciences of California (NASDAQ:PACB) Stock Crosses Above 200 Day Moving AverageTime to Sell? - MarketBeat
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market - sharewise.com
Pacific Biosciences of California (PACB) Stock Analysis: Navigating Growth Potential Amidst Market Challenges - DirectorsTalk Interviews
Pacific Biosciences of California unveils HiFiSequencing turning points at FOG2026 - Traders Union
Analyst Downgrade: Will Pacific Biosciences of California Inc outperform during market ralliesPrice Action & Safe Entry Point Alerts - baoquankhu1.vn
Finanzdaten der Pacific Biosciences Of California Inc-Aktie (PACB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.33%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):